96 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22616 | adjuvant, TNBC | Daphné t'Kint de Roodenbeke | Breast | AstraZeneca | OLYMPIA D081CC00006 BIG 6-13, NSABP B-55 | Trial closed for recruitment | A randomised, double-blind, parallel group, placebo-controlled multicentre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy (OLYMPIA study) | daphne.tkint@hubruxelles.be | 3 | 3 | |
| 22675 | Any line/RECIST v1.1/Eligible for platinium salt chemotherapy | Nuria Kotecki | Multiple | Onxeo | OX2016-203-01 | Trial closed | An open-label, dose-escalation, phase I study to assess the safety, pharmacokinetics and pharmacodynamics of AsiDNA, a DNA repair inhibitor administered intravenously in patients with advanced solid tumors | Nuria.Kotecki@hubruxelles.be | 1 | 1 | |
| 22772 | ER+/PR+/HER2-. Adjuvant. Palbociclib | Michail Ignatiadis | Breast | ABCSG | PALLAS | Trial closed for recruitment | PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer | michail.ignatiadis@hubruxelles.be | 3 | 3 | |
| 22610 | Adjuvant or neoadjuvant | Jean Klastersky | Breast | Institut Jules Bordet | Papaldo | Trial closed for recruitment | A phase II randomized study to verify the Papaldo's hypothesis : the effectiveness of a reduced dosing of G-CSF in chemotherapy-treated patients with a low to moderate risk of febrile neutropenia | jean.klastersky@hubruxelles.be | 2 | 2 | |
| 22825 | ER+/HER2- | Andrea Gombos | Breast | Institut Jules Bordet | PEARL | Trial closed | The PEARL study : Pet imaging as a biomarker of Everolimus Added value in hormone Refractory postmenopausaL women | accueil.oncologie@hubruxelles.be | 2 | 2 | |
| 22653 | HER 2 positive, first line | Philippe Aftimos | Breast | MedSir | PHERGain | Trial closed | Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: FDG-PET response-adapted strategy. The PHERGain study | philippe.aftimos@hubruxelles.be | 2 | 2 | |
| 22622 | ER+/HER2-. Adjuvant. End of hormonotherapy for pregnancy | Andrea Gombos | Breast | IBCSG | POSITIVE | Trial closed for recruitment | A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy | accueil.oncologie@hubruxelles.be | 3 | 3 | |
| 22648 | Activating EGFR mutation or HER2 mutation or HER3 mutation | Philippe Aftimos | Breast | UZ-Brussel | Precision 2 | Trial closed for recruitment | An open explorative phase II, open-label study of afatinib in the treatment of advanced cancer carrying an EGFR, a HER2 or a HER3 mutation | philippe.aftimos@hubruxelles.be | 2 | 2 | |
| 22624 | ER+/HER2-. Metastatic. Endocrine resistant. Palbociclib | Michail Ignatiadis | Breast | IBCSG | PYTHIA IBCSG 53-14 / BIG 14-04 | Trial closed | PYTHIA IBCSG 53-14 A Phase II Study of Palbociclib plus Fulvestrant for pretreated patients with ER+/HER2- Metastatic Breast Cancer | michail.ignatiadis@hubruxelles.be | 2 | 2 | |
| 28735 | Evandro De Azambuja | Breast | UZ-K.U.Leuven | RIBOB | Trial closed for recruitment | A phase IV Study to collect data on the efficacy and safety of RIBociclib in combination with letrozole in Older women (?70 years) with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced Breast cancer (aBC) with no prior systemic therapy for advanced disease | 4 | 4 | |||
| 28597 | Laurence Buisseret | Breast | Institut Jules Bordet | ROSALINE | Trial closed for recruitment | Neoadjuvant study of targeting ROS1 in combination with endocrine therapy in invAsive Lobular carcINoma of the breast | laurence.buisseret@hubruxelles.be | 2 | 2 | ||
| 29660 | Philippe Aftimos | Breast | IBCSG | SASCIA | Trial closed for recruitment | Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2 - negative breast cancer patients with high relapse risk after standard neoadjuvant treatment | philippe.aftimos@hubruxelles.be | 3 | 3 | ||
| 22848 | Smoker of quit smoking within the last 6 months, any tumors | Solid tumors | Institut Jules Bordet | Sevrage Tabagique | Trial open for recruitment | Impact of an emotion and craving regulation intervention on smoking cessation and maintenance among oncology patients : a randomized study | |||||
| 29408 | Michail Ignatiadis | Breast | Seagen | SGNTUC-028 - HER2CLIMB-05 | Trial closed for recruitment | A randomized, double-blind, phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic HER2+ breast cancer (HER2CLIMB-05) | michail.ignatiadis@hubruxelles.be | 3 | 3 |